DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
TAK-593 is an investigational drug.
There have been 348 clinical trials for TAK-593. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2020.
The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).
Recent Clinical Trials for TAK-593
|A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)||Janssen Pharmaceutical K.K.||Phase 3|
|A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers||Takeda||Phase 1|
|A Study of TAK-994 in Adults With Narcolepsy||Takeda||Phase 2|